Alphamab Oncology is a biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange, with the stock code:9966. We have created biomacromolecule platforms with independent intellectual property rights for drug discovery, research, development and manufacturing. Based on which, we can realize protein/antibody engineering, antibody screening, multi-module/multi-functional antibody modification. With advanced technology platforms, Alphamab Oncology has established a globally competitive and differentiated pipeline which covers single domain antibody/monoclonal antibodies, multi-functional antibodies, and antibody-drug conjugates.
We are actively looking for partners with global or regional coverage and capabilities:
Cooperation based on technology platforms:
● Partnership with our proprietary bispecific, mix-mAb and glycan-specific conjugation platforms.
Collaboration based on innovative products in oncology:
● KN035: PD-L1 single domain antibody, subcutaneous formulation
● KN046: PD-L1/CTLA-4 bispecific antibody
● KN026: HER2 bispecific antibody
● JSKN003: anti-HER2 bispecific ADC
Collaboration based on innovative product in autoimmune diseases or organ transplantation therapeutic:
● KN019: CTLA-4 fusion protein, subcutaneous formulation for rheumatoid arthritis and other autoimmune diseases
● KN019: CTLA-4 fusion protein, IV formulation for organ transplantation
WE ARE NOW OPEN FOR
Licensing
co-development
option deal
M&A
...
OUR PARTNERS
If you have an interest in one of these areas, please direct your inquiry to bd@alphamabonc.com
